Advertisement

Topics

Corvidia Therapeutics Inc. Company Profile

18:13 EDT 19th June 2018 | BioPortfolio

Corvidia Therapeutics Inc. is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardiovascular and cardio-renal therapies. Corvidia’s pipeline programs utilize functional genomics to precisely identify patients with unique sensitivity to specific biologic pathways, allowing for rapid development and an accelerated path-to-market for drugs targeting those pathways. Among our portfolio of novel therapeutic candidates, we presently have an experimental therapy in Phase 2 development for a genetically-defined patient population with chronic kidney disease. Corvidia’s other preclinical programs are in various stages of development and are focused on cardiovascular diseases. For more information, please visit www.corvidiatx.com


News Articles [771 Associated News Articles listed on BioPortfolio]

Corvidia CEO Davidson Moves to CSO, de Garidel Named Chief Executive

Corvidia Therapeutics’ CEO Michael Davidson is taking a new role at the company as its chief scientific officer. Waltham, MA-based Corvidia has appointed Marc de Garidel to succeed Davidson as chief...

Corvidia Therapeutics raises $60m funding to speed up clinical work

Corvidia Therapeutics has secured $60m in a Series B funding round to accelerate growth of its ongoing clinical programs, expand scientific and market access capabilities and explore new treatment are...

Funding round pulls in $60M for Corvidia

A round of Series B financing pulled in $60 million for Corvidia Therapeutics.  -More- 

Corvidia Raises $60 Million Series B to Push into the Clinic

Corvidia Therapeutics, headquartered in Waltham, Massachusetts, closed on a Series B funding round worth $60 million.

Appointments: Celgene's COO Departs, New CEOs At Abeona, Kleo and Corvidia And Board Changes

This week's company moves include the sudden departure of Celgene's COO, new CEOs at Abeona Therapeutics, Kleo Pharmaceuticals and Corvidia...    

Corvidia brings in $60mm through Series B

Corvidia Therapeutics Inc. raised $60mm in its Series B financing led by Venrock, which was joined by other new backers Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthca...

Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer

Aimed at further evolving Corvidia Therapeutics from clinical to commercial company de Garidel to replace Michael Davidson, M.D. who will stay on as ...

Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work

Lead investor Venrock joined by Andera, Cormorant, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH, Sofinnova Partners, Apple Tree Partners and MedIm...

PubMed Articles [426 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1236 Associated Companies listed on BioPortfolio]

Corvidia Therapeutics Inc.

Corvidia Therapeutics Inc. is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardiovascular and cardio-renal therapies...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Corvidia Therapeutics Inc." on BioPortfolio

We have published hundreds of Corvidia Therapeutics Inc. news stories on BioPortfolio along with dozens of Corvidia Therapeutics Inc. Clinical Trials and PubMed Articles about Corvidia Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Corvidia Therapeutics Inc. Companies in our database. You can also find out about relevant Corvidia Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record